Responses

Original research
Using nasal sprays to prevent respiratory tract infections: a qualitative study of online consumer reviews and primary care patient interviews
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Enhancing nasal antibody responses, mucosal vaccines may prevent SARS COV19 Omicron VOC infection and transmission more effectively, enabling greater control of the pandemic and limiting the emergence of

    Intramuscular (i.m.) ChAdOx1 nCOV19 , trade name "covishield " vaccine of company astrazeneca and sub licensed with Serum Institute of India ( mRNA 1273 vaccine for Spike Protein /RBD) and of Bharat Biotech company's whole virion inactivated Vero cell "co vaccine" which were given to Indian population in two minimum doses( free of cost) , in India ,were remarkably effective in preventing severe COVID-19 pneumonia, ARDS and hospitalisation with all sub variants( VOC) of omicron variants of concern of SARS COV-2 ,those were circulated so far in India since 2021 March and their full dose ( two/ or precautionary 3rd doses in 27% Indians ) use being associated with declining hospitalisation , ARDS, ventilation and COVID 19 related death . However, current vaccines those are given by the Indian government's health department can provide only transient protection against respiratory SARS- COV -2 viral replications , onward transmission and continuing emergence of variants of concern, by contrast, respiratory infection with SARS-CoV-2 could induces more potent serum IGg and IGa antibody mediated ( against spike protein and RBD protein) immunity against breakthrough infections ( re- infection even after vaccination or after clinical or subclinical infection) , mucosal immune defences that could inhibit viral replication and transmission, but did not happened it so in real world . Although covishield/ or co vaccine i.m. vaccinations transi...

    Show More
    Conflict of Interest:
    None declared.